The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis (2022)
Source: Frontiers Immunology. Unidade: IQ
Subjects: ESCLEROSE MÚLTIPLA, ADENOSINA, RECEPTORES
ABNT
SILVA, Eduardo Duarte et al. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Frontiers Immunology, v. 13, p. 1-10 art. 946698, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.946698. Acesso em: 01 set. 2024.APA
Silva, E. D., Ulrich, H., Giacomelli, Á. O., Hartung, H. P., Meuth, S. G., & Peixoto, C. A. (2022). The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis. Frontiers Immunology, 13, 1-10 art. 946698. doi:10.3389/fimmu.2022.946698NLM
Silva ED, Ulrich H, Giacomelli ÁO, Hartung HP, Meuth SG, Peixoto CA. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis [Internet]. Frontiers Immunology. 2022 ; 13 1-10 art. 946698.[citado 2024 set. 01 ] Available from: https://doi.org/10.3389/fimmu.2022.946698Vancouver
Silva ED, Ulrich H, Giacomelli ÁO, Hartung HP, Meuth SG, Peixoto CA. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis [Internet]. Frontiers Immunology. 2022 ; 13 1-10 art. 946698.[citado 2024 set. 01 ] Available from: https://doi.org/10.3389/fimmu.2022.946698